[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367409-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367409-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","implementing-high-risk-human-papillomavirus-self-sampling-for-cervical-cancer-screening-in-ghana-a-study-carciscan-protocol","Implementing High-Risk Human Papillomavirus Self-Sampling for Cervical Cancer Screening in Ghana: A Study (CarciSCAN) Protocol","","Protocol for evaluating a cervical cancer screening program in Ghana using high-risk human papillomavirus (hrHPV) self-sampling. The study targets 1,000 non-pregnant women aged 30–65, with hrHPV-positive participants undergoing visual inspection with acetic acid and offering ablation for high-grade lesions; biopsies are used when invasion is suspected or diagnosis is equivocal. Outcomes include successful screening proportion, uptake, and disease detection measures plus follow-up testing at 6 months and rescreening after 3 years for hrHPV-negative women.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/implementing-high-risk-human-papillomavirus-self-sampling-for-cervical-cancer-screening-in-ghana-a-study-carciscan-protocol/367409/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/implementing-high-risk-human-papillomavirus-self-sampling-for-cervical-cancer-screening-in-ghana-a-study-carciscan-protocol/367409.png","ImageObject",300,407,{"name":42,"@type":43},"WPS_1786070896","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the purpose of the CarciSCAN protocol in Ghana?","Question",{"text":63,"@type":64},"To evaluate the clinical efficacy of a cervical cancer screening program that uses hrHPV self-sampling among women in Ghana.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How are hrHPV-positive participants managed in the study?",{"text":68,"@type":64},"Women who test hrHPV positive undergo visual inspection with acetic acid; those diagnosed with high-grade squamous intraepithelial lesions are offered ablation, and biopsies are taken if invasion is suspected or diagnosis is equivocal.",{"name":70,"@type":61,"acceptedAnswer":71},"What follow-up schedule and outcomes are used to measure effectiveness?",{"text":72,"@type":64},"Women who are hrHPV positive and/or receive treatment will perform hrHPV self-sampling after 6 months, while hrHPV-negative women will rescreen after 3 years. The primary outcome is the proportion successfully screened (valid HPV test result among invited attendees), with secondary outcomes covering screening uptake and disease detection measures.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367409,1790478541,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},549768072016,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","| Implementing High-Risk Human Papillomavirus Self-Sampling for Cervical Cancer Screening in Ghana: A Study (CarciSCAN) Protocol | Cancer Control Volume 32: 1–9 © The Author(s) 2025 Article reuse guidelines:\u003Cbr>[sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/10732748251330698](DOI: 10.1177/10732748251330698)\u003Cbr>[journals.sagepub.com/home/ccx](journals.sagepub.com/home/ccx)\u003Cbr>\u003Cbr>|\n| --- | --- |\n| Nadja Taumberger, PhD 1,2, Ibrahim Friko, MD3, Vera Mwinbe-Ere Der4,\u003Cbr>Laura Burney Ellis, MD5,6, Amy MacDonald Shearer, MD6 􀀁, Sarah J. Bowden, PhD5,6, Maria Kyrgiou, PhD5,6, Teresa L. Pan, MD7, Verena Lessiak, MD8, Neli Hofer, MD2, Elisabeth Rogatsch, MD2, Manurishi Nanda, MD2, Isabella Pfniss, MD 1, Elmar Joura, MD9, Alper Cinar, BS 10, Yalin Kilic, PhD 10, and Murat Gultekin, MD 11\u003Cbr>Abstract\u003Cbr>Background: The World Health Organization (WHO) aims to eliminate cervical cancer by 2030 through a global strategy, centred on high-risk Human papillomavirus (hrHPV)-based screening and treatment. Implementing these strategies in lowresource settings remains challenging, due to barriers associated with limited healthcare infrastructure and patient awareness. Self-sampling for hrHPV has shown higher acceptability and similar diagnostic accuracy compared to clinician-taken samples. This study proposes a protocol to evaluate the clinical efﬁcacy of a cervical cancer screening program utilising hrHPV selfsampling in Ghana.\u003Cbr>Methods and Analysis: 1000 non-pregnant women aged 30-65 years will be invited to self-collect hrHPV samples. Those testing hrHPV positive will undergo visual inspection with acetic acid. Those diagnosed with high-grade squamous intraepithelial lesions will be offered ablation. In any case where there is a suspicion of invasion, or equivocal diagnosis, biopsies will be taken. Follow-up for women who are test positive for hrHPV and/or undergo treatment, will involve hrHPV self-sampling after 6 months. HrHPV-negative women will rescreen after 3 years. Biopsies will be taken where immediate treatment is not suitable, and women with conﬁrmed or suspected invasive cervical carcinoma will be referred for surgical and/or oncological care. The primary outcome will be the proportion of women successfully screened, deﬁned as the proportion of women with a valid HPV test result out of those invited to attend cervical screening. Secondary outcomes include screening uptake, disease detection |  |\n| 1 Department of Gynaecology, Krankenhaus der Barmherzigen Brüder, Graz, Austria |  |\n| 2Department of Obstetrics and Gynecology, Medical University of Graz, Austria |  |\n| 3Department of Obstetrics and Gynecology, Holy Family Hospital Techiman, Ghana |  |\n| 4Department of Research and Development, Holy Family Hospital Techiman, Ghana |  |\n| 5Imperial College London, Hammersmith Hospital, London, UK |  |\n| 6School of Medicine Imperial College London, Department of Metabolism, Digestion and Reproduction/Surgery and Cancer, Imperial College Healthcare NHS |  |\n| Trust, London, UK\u003Cbr>7Department of Obstetrics and Gynecology, Medical University Innsbruck, Austria |  |\n| 8Department of Obstetrics and Gynecology, State Hospital Villach, Austria |  |\n| 9Comprehensive Cancer Center, Medical University of Vienna, Austria\u003Cbr>10Department of Molecular Biology and Genetics, Bogazici University, ˙Istanbul, Turkey\u003Cbr>11 Faculty of Medicine, Department of Obstetrics and Gynecology, Division of Gynecological Oncology, Hacettepe University, Ankara, Turkey\u003Cbr>Corresponding Author:\u003Cbr>Laura Burney Ellis, Imperial College London, Hammersmith Hospital, London, UK; School of Medicine Imperial College London, Department of Metabolism, Digestion and Reproduction/Surgery and Cancer, Imperial College Healthcare NHS Trust, London, UK.\u003Cbr>Email: [laura.ellis@imperial.ac.uk](laura.ellis@imperial.ac.uk) |  |\n\nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of ","cbCaioCAl0uYEQdU","https://ap.wps.com/l/cbCaioCAl0uYEQdU","pdf",801613,"English","# Abstract\n## Background\n## Methods and Analysis\n## Discussion\n## Trial Registration\n## Plain Language Summary","[{\"question\":\"What is the purpose of the CarciSCAN protocol in Ghana?\",\"answer\":\"To evaluate the clinical efficacy of a cervical cancer screening program that uses hrHPV self-sampling among women in Ghana.\"},{\"question\":\"How are hrHPV-positive participants managed in the study?\",\"answer\":\"Women who test hrHPV positive undergo visual inspection with acetic acid; those diagnosed with high-grade squamous intraepithelial lesions are offered ablation, and biopsies are taken if invasion is suspected or diagnosis is equivocal.\"},{\"question\":\"What follow-up schedule and outcomes are used to measure effectiveness?\",\"answer\":\"Women who are hrHPV positive and/or receive treatment will perform hrHPV self-sampling after 6 months, while hrHPV-negative women will rescreen after 3 years. The primary outcome is the proportion successfully screened (valid HPV test result among invited attendees), with secondary outcomes covering screening uptake and disease detection measures.\"}]","Implementing High-Risk Human Papillomavirus Self-Sampling for Cervical Cancer Screening in Ghana: A Study (CarciSCAN) Protocol | PDF",1790170658,23,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/45a3250e3ce7ebe083ea8fd9eac09100.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1601fe0839cc697e9eea4aa47eba4609.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8e599b163ac07fa8303938a309b2dbc8.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa47fd8cb9108306a4edbabbb8a5af4c.webp",980,1268]